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Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR
monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations
in order to identify additional biomarkers of cetuximab efficacy.
Methods: Previously genotyped (KRAS, NRAS, BRAF, PIK3CA mutations) formalin-fixed paraffin-embedded tumour
biopsies of 226 cetuximab-treated CRC patients (1st to 3rd line therapy) were assessed for mRNA expression of
epidermal growth factor receptor (EGFR) and its ligands EGF, Transofrming Growth Factor-a (TGFA), Amphiregulin
(AREG) and Epiregulin (EREG) with real time quantitative PCR. Mutations were detected in 72 (31.9%) tumours for
KRAS, in 6 (2.65%) for BRAF, in 7 (3.1%) for NRAS and in 37 (16.4%) for PIK3CA.
Results: Only PIK3CA mutations occasionally coexisted with other gene mutations. In univariate analysis, prognostic
significance for survival ( from metastases until death) was seen for BRAF mutations (Hazard Ratio HR 8.1, 95% CI
3.4-19), codon 12-only KRAS mutations (HR 1.62, 95% CI 1.1-2.4), high AREG mRNA expression only in KRAS wild
type CRC (HR 0.47, 95% CI 0.3-0.7) and high EREG mRNA expression irrespective of KRAS mutation status (HR 0.45,
95% CI 0.28-0.7). EREG tumoural mRNA expression was significantly associated with a 2.26-fold increased likelihood
of objective response to cetuximab therapy (RECIST 1.1). In multivariate analysis, favourable predictive factors were
high AREG mRNA in KRAS wild type tumours, high EREG mRNA, low Ephrin A2 receptor mRNA. Cetuximab-treated
patients with AREG-low KRAS wild type CRC fared very poorly, their survival being similar to KRAS mutant CRC.
Patients with KRAS codon 13 or other non-codon 12 mutations had a median survival (30 months, 95% CI 20–35)
similar to that of patients with KRAS wild-type (median survival 29 months, 95% CI 25–35), in contrast to patients
with KRAS codon 12 mutations who fared worse (median survival 19 months, 95% CI 15–26).
Conclusions: BRAF and codon 12 KRAS mutations predict for adverse outcome of CRC patients receiving
cetuximab. AREG mRNA reflects EGFR signalling in KRAS wild type tumours, predicting for cetuximab efficacy when
high and failure when low. EREG may have a prognostic role independent of KRAS mutation.
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Colorectal cancer (CRC) is among the «big killers» in
populations of developed societies, with a reported death
toll of 50,000 yearly in the United States [1]. Recent
advances in modern therapeutic strategies resulted in
significant survival improvement of patients with meta-
static disease. The Epidermal Growth Factor Receptor
(EGFR) on the cancer cell surface relays signals of
proliferation, angiogenesis, metastasis and antibodies
binding it have been partly responsible for the observed
outcomes improvement [2]. Cetuximab, a chimeric
IgG1 monoclonal antibody (moAb) and panitumumab,
a humanised IgG2 moAb are currently licensed for the
treatment of patients with metastatic colorectal cancer
either in combination with chemotherapy in the first
and second line setting or as monotherapy for refrac-
tory disease. The need to identify tumours addicted to
EGFR signalling and thus amenable to anti-EGFR
therapeutic modulation became apparent early on, as
response rates to cetuximab regimens in unselected
patient populations were typically lower than 30% [3].
KRAS is a cytoplasmic GTP-binding protein with low
inherent GTPase activity. When the KRAS protein is
bound to GTP, it relays signals of cellular proliferation
and inhibition of apoptosis, acting as a typical oncogene.
KRAS mutations were observed mainly in gene exon 2,
resulting in abrogated GTPase activity and locking the
KRAS protein in the active KRAS-GTP conformation.
By activating the RAS/RAF/MAPK axis downstream of
EGFR, these mutations render therapeutic modulation
of EGFR irrelevant [4]. Indeed, clinical data confirmed
the predictive value of KRAS exon 2 mutations for resist-
ance to cetuximab and panitumumab, leading to the li-
cense of these moAbs exclusively for the management of
patients with KRAS-wild type colorectal cancers [5-7].
Despite application of such a «negative selection» bio-
marker, the KRAS-wild type patient population benefits
from anti-EGFR strategies in less than half of cases. Re-
search efforts towards identification of additional predictive
biomarkers have generated interesting, though preliminary
and at times conflicting data on the importance of tumour
mRNA levels of EGFR ligands, of activating mutations in
other genes such as BRAF, PIK3CA [8-11]. Finally, the
codon localisation of KRAS mutations was found to pos-
sess differential transforming potential in cell cultures and
to bear distinct predictive value for cetuximab resistance in
clinical series [9].
We report a retrospective translational research project
on previously diagnosed formalin-fixed paraffin-embedded
(FFPE) colorectal carcinomas from 226 patients who were
treated with cetuximab-based therapy in the first, second
or third line setting for metastatic disease. In the context
of a broad translational research protocol involving ex-
ploratory analyses of multiple biomarkes, our EGFR axisproject aimed at screening for biomarkers of cetuximab
benefit. It included studying gene expression of EGFR, its
ligands epidermal growth factor (EGF), amphiregulin
(AREG), epiregulin (EREG), transforming growth factor-a
(TGFa) and the presence of activating mutations in KRAS,
BRAF, NRAS, PIK3CA genes as well as the possible dis-




Two hundred and twenty-six patients with histologically
established diagnosis of colorectal adenocarcinoma, for
whom collection of tissue samples was part of their rou-
tine care and treatment, provided informed consent for
the research use of their biologic material. The retro-
spective translational research protocol was approved by
the Ethics Committee/Scientific Council of the General
Hospital Papageorgiou, Thessaloniki (Meeting number
158/26-6-12). The study was performed in compliance
with NCI-EORTC’s REMARK recommendations. Upon
development of metastatic disease, these patients were
managed with cetuximab-based therapy from May 2004
until December 2008 in Hellenic Cooperative Oncology
Group (HeCOG)- affiliated centers. All FFPE blocks
were retrospectively identified and quality-controlled by
an experienced pathologist (Despina Televantou, DT) for
the histological diagnosis of colorectal adenocarcinoma
and for the assessment of tumour cell content. In case of
less than 50% tumour cells in whole sections, manual
tumour macrodissection was applied before further
processing. Thus, all molecular samples contained mo-
lecular templates (DNA, RNA) above the 50% threshold.
Tissue material and molecular studies
In total, 226 tissue blocks were available for DNA ana-
lysis. DNA samples had been centrally assessed for
KRAS, NRAS, BRAF and PIK3CA mutations by using a
Sequenom MALDI-TOF MassARRAY multiplex PCR
method and the Sequenom MassARRAY Assay Design
3·1 software as previously published [8].
Corresponding sections or macrodissected tissue fragments
from 199 available tissue blocks were lysed overnight
and processed for RNA extraction with TRIZOL-LS
(Invitrogen/Life Technologies, Paisley, UK), according
to the manufacturers’ instructions. RNA was reverse
transcribed with Superscript III and random hexamers
(Invitrogen/Life Technologies). cDNAs were normalized
at 25 ng/ul and stored at -20°C until use. mRNA expres-
sion was assessed with Taqman-MGB assays (Applied
Biosystems/Life Technologies) for exon spanning am-
plicons, for the following targets with data in parentheses
corresponding to assay ID, reference sequence, loca-
tion and size of amplicon, in the same order: AREG
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(Hs01099999_m1, NM_001963.3, exons 20–21, 70 bp);
EGFR (Hs00193306_m1, NM_005228.3, exons 20–21,
69 bp); EREG (Hs00914313_m1, NM_001432.2, exons 3–
4, 65 bp); and, TGFa (Hs00608187_m1, NM_001099691.1,
NM_003236.2, exons 4–5, 70 bp).
Samples were run in duplicates in an ABI7900HT real
time PCR system along with negative (no-template) and
positive controls (commercially available reference RNA:
TaqManW Control Total RNA, cat. no 4307281, Applied
Biosystems/Life Technologies). As an endogenous control
and for the normalization of CT (cycle threshold) values,
an assay targeting GUSB mRNA (beta-glucuronidase
[#4333767 F]) was used. GUSB was preferred over usually
applied endogenous controls because (a) no pseudogenes
have as yet been reported for this gene, and (b) it has been
identified as one among the best preserved mRNA targets
in FFPE tissues [12]. To obtain linear Relative Quantifica-
tion (RQ) values, relative expression was assessed as (40-
dCT), as previously described, whereby dCT (or deltaCT)
was calculated as (average target CT) – (average GUSB
CT) from all eligible measurements [13]. Samples were
considered eligible for analysis when both GUSB CTs in
duplicates were <36 and when duplicate dRQ values
(dRQ1 – dRQ2) were <0.85. As observed upon consecutive
runs of 30 eligible samples (15% of all samples), minimum-
maximum deltaRQs for all assays were <1.5 (AREG: 0.43;
EGF: 0.85; EGFR: 1.2; EREG: 0.69; TGFa: 0.64). RNA stud-
ies were performed in the Laboratory of Molecular Oncol-
ogy, Aristotle University of Thessaloniki, Greece.
Endpoints
The study endpoints were a) Survival, from the time of diag-
nosis of metastatic disease until death or last follow-up, b)
Best objective response rate (ORR) to any line of cetuximab-
based therapy by RECIST 1.1 criteria [14]. A progression-
free survival endpoint was not used intentionally because in
the setting of cetuximab use in various lines of therapy, it
could be influenced by the distribution of cetuximab therapy
line in various categories of biomarkers under study.
We analysed the prognostic/predictive impact of different
types of mutations of KRAS (codon 12 versus codon 13 ver-
sus other mutations versus wild type) and PIK3CA genes
(exon 9 versus exon 20 versus wild-type). We also compared
outcomes of cases with complex mutational phenotypes for
prognostic/predictive utility. Complex Genotype comparison
1 (CG1) compared outcomes of KRAS wild type versus
KRAS mutant versus [PIK3CA mutant + (KRAS or BRAF
mutant)]. CG comparison 2 (CG2) compared outcomes of
PIK3CA wild type versus PIK3CA mutant versus [PIK3CA
mutant + (KRAS or BRAF mutant)], while CG comparison
3 (CG3) outcomes of all KRAS, BRAF, PIK3CA wild type
versus any of them mutant versus [PIK3CA mutant +
(KRAS or BRAF mutant)].Statistical analysis
Cut-offs for each mRNA marker were selected either as nat-
ural breaks in the distributional profiles of the corresponding
RQ values or, if these were not apparent, as RQ value
quartiles, which were examined for statistically significant
associations with survival at the 5% significance level. If a
cut-off was statistically significant it was used to classify low
and high expressing tumours. In the absence of a candidate
cut-off, mRNA markers were examined as continuous
variables. The criterion for selecting cut-offs was the mini-
mum p-value method. In cases of more than one plausible
candidate points, graphical diagnostic plots using martingale
residuals were used for time to event endpoints and the
method of Miller and Seigmund for ORR [15]. Time-to
-event distributions were estimated using Kaplan-Meier
curves. Associations between biomarkers, mutations and
basic patient and tumour characteristics were examined
using the Fisher’s exact test or the Chi-Square test. Cox pro-
portional hazards and logistic regression were used for
univariate survival and ORR analyses respectively. Significant
correlations between parameters were tested as interactions
for prognostic significance in terms of survival and ORR.
The multivariate model contained every significant variable
and interaction from univariate analyses. A backward selec-
tion procedure with 15% removal cut-off was used.
The major aim of our research proposal is the characterization
of molecular biomarkers which would help to predict sur-
vival to cetuximab therapy. The study’s power justification
scheme was based upon the following assumptions: a)
expected follow up of 60 months, based on 56 months ac-
crual duration with 2 years additional follow-up period b)
ratio of expressed to non-expressed samples of either 1:3,
1:1 or 3:1 and c) HR of 0.4-0.5. With this background in-
formation and risk assumptions the sample of 226 patients
provided power from 91% to 99% at the 5% level of signifi-
cance for performing a two sided log-rank test.
Results
Patient and tumour demographics
A total of 226 patients of a median age of 62.6 years
(range 26–85) underwent excisional or incisional biopsy
of colorectal adenocarcinoma, of whom 83 (36.8%) were
diagnosed with localised (stage I-III) colon cancer and
137 (60.6%) with metastatic disease (Table 1). The pri-
mary tumour was located in the left colon (distal trans-
verse to rectum) in 165 (73.0%) of cases and in the right
colon (caecum to proximal transverse) in 60 (26.6%).
Rectal tumours accounted for 71 cases (31%).
From May 2004 until December 2008, cetuximab had
been administered as an intravenous infusion according to
standard regimens (loading dose 400 mg/m2 followed by
weekly 250 mg/m2) as monotherapy (42, 13.4%) or with
regimes based on irinotecan (153, 48.7%), oxaliplatin (84,
26.7%) or both agents (29, 9.2%). The lines of therapy
Table 1 Disease demographics and management data
Parameter N (%)
Age (median) 62.6 years




Obstruction Yes/No 30 (13.2%)/179 (79.2%)
Perforation Yes/No 9 (4.0%)/201 (89.0%)
Primary Site Left/Right 165 (73.0%)/60 (26.6%)
Rectum 71 (31.0%)
TNM stage at biopsy
I-III versus IV 83 (36.8%)/137 (60.6%)
Median Follow Up 73.6 months
Deaths 175 (77.4%)
Line of therapy at Cetuximab
administration
1st line 38 (16.8%)
2nd line 108 (47.8%)
3rd line and beyond 80 (35.4%)
Type of therapy at Cetuximab administration
Irinotecan-based 153 (48.7%)
Oxaliplatin-based 84 (26.7%)
Both irinotecan and oxaliplatin 29 (9.2%)
Only fluoropyrimidine 6 (1.9%)
Single-agent Cetuximab 42 (13.4%)
Objective Response to Cetuximab
All lines of therapy
Complete Respone (CR) 2 (0.9%)
Partial Response (PR) 55 (24.4%)
ORR (CR+PR) 57 (25.3%)
Stable disease (SD) 66 (29.3%)
Progressive disease (PD) 70 (31.1%)
ORR by line of Cetuximab therapy
1st line 17 (44.7%)
2nd line 23 (21.5%)
3rd line 14 (22.9%)








AREG 168 39.9 38.7-40.9
EREG 160 36.4 34.7-37.9
EGF 167 29.3 27.9-33.6
TGFa 162 37.1 36.2-37.9
EGFR 168 38.3 37.7-39.2
KRAS N=205





















All mutations 37 (16.4%)
Exon 9 20 (8.8%)
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38 (16.8%), 2nd line in 108 (47.8%), 3rd and beyond in 80
(35.4%) (Table 1). Of note, as the period of therapy
extended from 2004 until December 2008, an unselected
patient population received cetuximab-based therapies, ir-
respective of KRAS mutational status.
mRNA markers and somatic genotypes
Out of the 199 samples tested for mRNA expression,
three were found not eligible for all targets. In total,84.4% of samples were eligible for AREG analysis; 83.9%
for EGF; 84.4% for EGFR; 80.4% for EREG; and 81.4%
for TGFa. Out of the 226 DNA samples screened for the
presence of mutations, genotyping was successful in 205
samples for KRAS (90.8%), 159 (70.4%) for NRAS, 220
for BRAF and 220 for PIK3CA (97.3% in each case)
(Table 2). KRAS mutations were detected in 72 tumours
(31.9%), mostly in exon 2, in codon 12 in 45 cases
(20.0%) and in codon 13 in 16 cases (7.0%), while BRAF
V600E mutations were found in 6 cases (2.6%). NRAS
mutations were also quite rare, found only in 7 cases
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(16.4%), 20 in exon 9 (8.8%) and only five in exon 20
(2.2%). This genotypic analysis was included in a previ-
ous publication [8].
Correlation analysis revealed that mutations in KRAS,
BRAF, NRAS genes were mutually exclusive in all
evaluable cases. On the contrary, mutations in the
PIK3CA gene co-existed with KRAS mutations in 17
cases and with NRAS mutations in two. Statistically sig-
nificant associations at the 2-sided p<0.05 level were
seen between wild type status of KRAS, BRAF genes and
high AREG, EREG, EGFR mRNA levels. Among KRAS-
wild type cases, 81.4% were seen in AREG-high and
57.4% in EREG-high tumours, while of KRAS-mutated
cases only 63.9% were observed in AREG-high and only
35.7% in EREG-high tumours. Similarly, among BRAF-
wild type cases, 76.1% were seen in AREG-high and
50.7% in EREG-high tumours, while of BRAF-mutated
cases only two out of six (33.3%) were observed in
AREG-high and none in EREG-high tumours. Regarding
the primary location, 64.8% of KRAS mutations (p=0.07)
and 58% of PIK3CA mutations (p=0.036) occurred in
left-sided colorectal tumours, whereas four (66.7%) of BRAF
mutations in right-sided colon carcinomas (p=0.024). mRNA
RQ values were examined as continuous variables and sig-
nificant correlations at Spearmann’s R>0.4 were found be-
tween AREG and EREG mRNA (R=0.63, 95% CI 0.53-0.72,
p=0.0005).
Factors with predictive significance at univariate analysis
At a median follow-up of 73.6 months, 215 patients
(95.1%) had experienced disease progression and 163
(93.1%) had died. The median survival was was 27 -
months (95% CI 25–31). At univariate analysis, in the
present cohort of patients treated with cetuximab the
presence of BRAF mutations was significantly associated
with an 8.1-fold increased risk of death compared to
patients harbouring BRAF-wild type tumours. When all
types of mutations were pooled for each gene, KRAS
(HR 1.28, p=0.14), NRAS (HR 1.43, p=0.36) and PIK3CA
(HR 1.27, p=0.25) mutations did not have prognostic/
predictive utility. However, when types of mutations
were analysed separately for each gene, KRAS codon 12
mutations were predictive for increased risk of death
(HR 1.62, p=0.014).
Among parameters studied for gene expression, only
the 25th percentile of AREG mRNA values and the 75th
percentile of EREG mRNA values dichotomized cases
into groups with different outcome and were selected as
optimal cut-offs. None of EGF, TGFa, EGFR mRNA
levels disclosed cut-off points of prognostic significance.
Cetuximab therapy in patients harbouring AREG-high
(HR 0.47, p=0.0002) or EREG-high (HR 0.45, p=0.0009)
tumours resulted in reduced risk of death. EGFR, EGF,TGFa mRNA expression had no significant prognostic/
predictive value, either in the entire cohort or in the
KRAS-wild type versus KRAS mutant cases.
Regarding objective tumour response to any line of
cetuximab-based therapy, tumoural AREG and EREG
mRNA expression levels were associated with tumour
shrinkage as continuous variables. AREG was not
statistically significant as categorical variable but EREG
mRNA at the 75th percentile was associated with a 2.26-
fold increased likelihood of tumour response to cetuximab
compared to tumours with lower EREG mRNA expres-
sion. AREG failed to predict response in either KRAS wild
type or mutated cases. The expression levels of EREG in
the tumours of responding and non-responding patients
by KRAS gene status is depicted in a waterfall plot
(Figure 1). Of note, in an exploratory analysis, the predict-
ive significance for objective response was maintained
only in KRAS mutated CRC, in which EREG had an odds
ratio for response of 5.4 (95% CI 1.2-23.8, p=0.024). By
contrast, in KRAS-wild type tumours EREG failed to sig-
nificantly predict for response to therapy (OR 2.2, 95% CI
0.83-5.86, p=0.11). EGF, TGFa and EGFR mRNA expres-
sion had no predictive utility for response to cetuximab in
the whole cohort, neither in KRAS wild-type or KRAS
mutated cases. All factors with potential predictive utility
for cetuximab benefit are summarized in Table 3.
Interactions and factors with predictive utility at
multivariate analysis
Significant interactions (at the 1% significance level) be-
tween study variables for prognostic/predictive utility
(survival, ORR) were sought. In terms of impact on
survival, significant interactions were found between
AREG mRNA levels and mutational status of the KRAS
gene (p=0.0033). High mRNA levels of AREG predicted
for longer survival in patients with KRAS wild-type (me-
dian survival 33 vs. 15 months, p=0.0005, Figure 2), but
not in KRAS mutant tumours (median survival 22 vs.
17 months, p=0.64). In contrast, high mRNA levels of
EREG were associated with favourable prognosis irre-
spective of KRAS mutational status. In KRAS wild type
cases, the median survival was 37 months for EREG-high
as compared to 23 months for EREG-low expressing
tumours (p=0.01), while in KRAS mutated tumours me-
dian survival was 33 versus 19 months (p=0.02) in EREG-
high vs. low cases (Figure 3). Similar findings for EREG
high vs. low were seen when we examined complex cancer
genotypes: a) KRAS+BRAF, both wild type vs. any mutant,
b) KRAS+BRAF+PIK3CA+NRAS, all wild type vs. any mu-
tant. AREG mRNA had a favourable predictive significance
in wild type cases only, whereas EREG mRNA preserved
its significance in wild type as well as in mutant cases.
A multivariate analysis was performed in the context of
a broader mRNA profiling project of several biomarkers
a) KRAS wild type tumours 
b) KRAS mutant tumours 
Figure 1 Waterfall plot of tumoural EREG mRNA levels in responding and non-responding patients by KRAS mutation status. a) KRAS
wild type tumours, b) KRAS mutant tumours. X-axis corresponds to the 75th percentile EREG mRNA RQ values.
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HER3, HER4, Table 4). In the presence of wild-type KRAS,
high AREG mRNA levels were independently associated
with 83.0% reduction in the risk of death compared to
patients with AREG-low tumours. High EREG tumoural
mRNA was a favourable outcome predictor for cetuximab-
treated patients, irrespective of KRAS mutation status. High
Ephrin A2 (EphA2) mRNA and advanced age were adverse
independent prognosticators. Finally, among cetuximab-treated patients with AREG-low tumours, those with
mutant KRAS fared significantly better than patients
harbouring colon cancer with KRAS wild type (81%
decreased risk of death).
Impact of distinct types of KRAS and PIK3CA mutations
on outcome of cetuximab-treated patients
We examined different types of KRAS and PIK3CA
mutations for potentially distinct impact on patient
Table 3 Prognostic/predictive factors at univariate analysis




AREG mRNA (25th percentile) 0.47 0.31-0.70 0.0002
High 124 29
Low 40 16
EREG mRNA (75th percentile) 0.45 0.28-0.72 0.0009
High 39 36
Low 117 23
BRAF 8.1 3.44-19.0 0.00005
Mutation 6 12
Wild type 208 28
KRAS codon 12 1.62 1.10-2.38 0.014
Mutation 44 19
Wild type 129 29
Predictive for Response Odds Ratio
for Response
95% CI 2-sided P
AREG mRNA at 25th percentile 1.59 0.67-3.77 0.29
High vs. Low
EREG mRNA at 75th percentile 2.26 1.04-4.91 0.04
High vs. Low
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with codon 12 mutations had a median survival of 19 -
months (95% CI 15–26), significantly lower (p=0.033)
than the median survival of patients with other KRAS
mutations (30 months, 95% CI 20–35) and that of
patients with wild-type KRAS (29 months, 95% CI 25–
35). Further subgroup analyses showed that the median
survival in patients with codon 12 KRAS mutations was
also lower than the median survival of all other patient
subgroups (other KRAS mutations or KRAS wild-type).
Specifically, patients with codon 13 mutations reached a
median survival of 28 months (95% CI 16–39), those
with other rarer KRAS mutations a median survival of
33 months (95% CI 16–42) and patients with KRAS
wild-type tumours a median survival of 29 months (95%
CI 25–35). Despite the rather small size of compared
subgroups, a trend for statistical significance was evident
(p=0.068, Figure 4). No difference in patient outcomes
was found when we compared tumours with PIK3CA
exon 9 versus exon 20 mutations versus PIK3CA wild-
type status, as survival times clustered from 25 to 29 -
months (p=0.31). The only complex genotype that
harboured significance for cetuximab benefit was CG3
(p=0.019): Patients with tumours wild-type for all
PIK3CA, KRAS, BRAF reached a median survival of 32 -
months (95% CI 25–36), those with a PIK3CA mutation
along with KRAS or BRAF mutation had a median sur-
vival of 26 months (95% CI 16–32) while patients with
any single mutation in KRAS, BRAF or PIK3CA geneshad a median survival of 22 months (95% CI 19–28).
Apparently, concurrent mutations in PIK3CA along with
KRAS or BRAF mutations carried rather weak additional
adverse prediction.
Discussion
Despite exclusion of 30-40% of patients with KRAS-
mutant tumours, cetuximab-based regimens fail in more
than half of patients bearing KRAS wild-type colorectal
cancer [5-10]. We sought to screen for additional pre-
dictive biomarkers in a retrospective clinical series of
226 cetuximab-treated advanced CRC patients and to
look for hypothesis-generating hints of efficacy or resist-
ance. Despite homogeneous management of all patients
in standardised HeCOG recommended therapies, the
retrospective nature of the translational research is an
inherent limitation. Moreover, in the absence of a con-
trol arm with no treatment it is impossible to speculate
on the prognostic (impact on outcome irrespective of
therapy) or predictive (impact on benefit from cetuximab
therapy) effect of the biomarkers studied. Finally, the admin-
istration of cetuximab across several lines of therapy
combined with various chemotherapeutic agents constitutes
an additional layer of heterogeneity, masking possible
interactions and confounders. Moreover, survival analysis
will not be robust and even tumor response may be
influenced by the chemotherapy backbone to which
cetuximab was added. Finally, it would be ideal for all of
the tissue samples to have been collected prior to
a) KRAS wild-type (p=0.0005) 
b) KRAS mutated (p=0.64) 
Figure 2 Impact of AREG mRNA levels on cetuximab-treated patient survival by KRAS tumour mutation. (Blue line: AREG-high, Red line:
AREG-low). a) KRAS wild-type (p=0.0005), b) KRAS mutated (p=0.64).
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may have changed by the time patients received 1st, 2nd or
3rd line therapy.
The incidence of observed KRAS, BRAF, NRAS,
PIK3CA mutations are in line with those in the literature,
ranging from 30-43% for KRAS, 0.5-7.2% for BRAF, 2-4%
for NRAS, 5-17% for PIK3CA [8,16-19]. In univariate ana-
lysis, BRAF mutations were associated with an 8-fold
increased risk of death, while KRAS mutations incurred a
weaker, less than 2-fold increase in the risk of death only
when codon 12 mutations were analysed separately. Simi-
lar to our findings, Souglakos et al. reported a markedly
increased risk of death with a multivariate HR of 5.1 for
BRAF mutations in cetuximab-treated CRC patients [20].Moreover, Modest et al. recently reported median survival
times of 23.5 months in KRAS wild-type, 18.9 months in
KRAS codon 12-mutated and only 13 months in BRAF-
mutated CRC patients on cetuximab-based first-line ther-
apy [21]. Seemingly, BRAF mutation seems to carry espe-
cially adverse prognosis in patients who receive anti-EGFR
therapeutic modulation.
We observed no prognostic effect of NRAS, PIK3CA
or KRAS mutations outwith codon 12. Despite initial
reports of significant negative correlation between
PIK3CA mutations and response to anti-EGFR moAbs,
series by Prenen et al. and Saridaki et al. failed to find
such an association [10,18]. De Roock et al. suggested
that only exon 20 PIK3CA mutations were associated




Figure 3 Impact of EREG mRNA levels on cetuximab-treated patient survival by KRAS tumour mutation. (Blue line: EREG-high, Red line:
EREG-low). a) KRAS wild type (p=0.011), b) KRAS mutated (p=0.022).
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http://www.biomedcentral.com/1471-2407/13/49with resistance to cetuximab therapies [8,22]. In our
series, only 5 tumours with exon 20 PIK3CA mutations
were detected. Regarding KRAS, the same group reported
in a pooled dataset of 579 cetuximab-treated CRC patients
that those with codon 13 KRAS mutant tumours (G13D)
had better outcomes (HR for death 0.50) compared to
patients with other KRAS mutant tumours [9]. Those
findings stood in our Greek population cohort, as the me-
dian survival of our cetuximab treated patients seemed to
de-escalate from 29–33 months for KRAS wild type to 28 -
months for the KRAS codon 13 mutated group, dropping
to 19 months for the KRAS codon 12 mutated group. Al-
though Peeters et al. recently failed to find a prognostic
difference between codon 12 and codon 13 KRAS
mutations in CRC patients managed with panitumumab
in three randomised trials, another group from Germany
did so for cetuximab [21,23,24]. KRAS codon 12 mutantCRC patients reached a median survival of only 18.9 -
months versus 23.5 months for KRAS wild type and 26.2 -
months for KRAS codon 13 mutant CRC patients on first
line cetuximab+CAPIRI/CAPOX. Indeed in preclinical
experiments, transforming potential, RAS/GTP activation,
MAPK phosphorylation and tumour growth were markedly
increased in the presence of KRAS codon 12 mutations,
followed in decreasing order by codon 13, 61, 117 and 146
mutations [25,26]. Moreover, microarray profiling of multi-
gene expression signatures associated with KRAS mutations
revealed that codon 12 mutations were linked to a gene
cluster distinct from all other KRAS mutations [25]. Further
validation of these data is warranted in order to confirm or
refute the hypothesis that specific molecular characteristics
of KRAS mutations are determinants of cetuximab benefit.
We observed a strong correlation of increased
tumoural mRNA of AREG, EREG with clinical benefit
Table 4 Prognostic/predictive factors at multivariate
analysis
Survival (N=136) HR 95% CI Wald-p
Age
> median 1.64 1.08-2.48 0.0199
EPHA2
High vs. Low 1.67 1.05-2.63 0.0287
EREG
High vs. Low 0.38 0.21-0.66 0.0006
AREG/KRAS interaction 7.98 2.98-21.40 <.0001
AREG high in KRAS mutant vs
AREG high in KRAS wild type
AREG
AREG high vs. low for KRAS wild type 0.17 0.08-0.34 <.0001
AREG high vs. low for KRAS mutant 1.33 0.67-2.61 0.4165
KRAS
KRAS mutant vs. wild type for AREG high 1.49 0.90-2.45 0.1184
KRAS mutant vs. wild type for AREG low 0.19 0. 08–0.43 <.0001
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keeping with data reported by four other groups
[11,20,27,28]. Gene expession of the two ligands, which
are collocalised on chromosome 4q13.3 and produced
by tumour cells in autocrine fashion, was tightly
correlated and occurred more often in KRAS and BRAF
wild type tumours. The correlation of low EREG/AREG
expression with KRAS or BRAF mutated status could be
due to the constitutive activation of the RAS/RAF/
MAPK pathway which makes activation of the EGFR
pathway redundant biologically. Alternatively, it could beFigure 4 Survival of cetuximab-treated patients by type of KRAS mut
mutations, Green line: wild-type, Purple line: other KRAS mutations.due to a negative feedback loop linking MAPK axis acti-
vation with suppression of the EGFR pathway.
Objective response to anti-EGFR therapy was correlated
to continuous expression levels of AREG, EREG but only
to categorical EREG mRNA distribution, intriguingly
more strongly in KRAS mutated cases. The smooth nature
of relationship between marker levels and outcome,
resulting in lack of a universal cut-point applicable in all
clinical situations has already been reported by Jacobs
et al. [11]. In the presence of downstream activation of the
EGFR/RAS/MAPK axis due to mutated KRAS effector,
gene expression of AREG, EREG ligands would be bio-
logically irrelevant for benefit from cetuximab. In our
series this was the case for AREG, however tumour EREG
mRNA retained predictive significance for survival both in
KRAS wild-type as well as mutated cases, a counter-
intuitive finding, further supported by the predictive sig-
nificance of EREG for response, even in KRAS mutant
patients. AREG and EREG are not biologically identical:
AREG binds EGFR only, whereas EREG binds EGFR and
HER4 and leads to a prolonged state of receptor acti-
vation [29]. Compared to AREG, tumour EREG mRNA
expession was a stronger predictor of cetuximab bene-
fit in KRAS wild type cases in three more series
[13,20,27]. Consequently, we may speculate that even
in the presence of KRAS mutations, cetuximab binding
to EGFR prevents high levels of EREG from activating
HER1/HER4 heterodimers and thus abrogates signal-
ling pathways distinct from RAS/MAPK. In fact, Baker
et al. reported HER4 gene expression as one of the
genes significantly associated with clinical benefit in
144 cetuximab-treated CRC patients [28]. However,
our findings should be interpreted with caution as theation in tumour. Blue line: codon 12 mutations, Red line: codon 13
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low (n=10) and random effects cannot be excluded.
In our cohort, the survival of cetuximab-treated patients
with KRAS wild type, AREG-low CRC (median 15 months)
was as poor as the survival of patients with KRAS mutant
tumours (17–22 months). If this finding is confirmed in
independent series, AREG expression in KRAS wild type
cases would emerge as a robust biomarker of cetuximab
efficacy. Baker et al. suggested the use of a 4-gene score
(AREG, EREG, DUSP6, SLC26A3) for the prediction of
anti-EGFR treatment benefit in KRAS wild type CRC [28].
In the presence of low AREG and thus inactive EGFR
pathway, cetuximab binding to HER dimers might
elicit a paradoxical «pro-survival» cellular response via
MAPK-dependent and MAPK-independent pathways,
as suggested by Oliveras-Ferraros et al. [30]. Finally,
the markedly increased risk of death (8-fold) of high
AREG mRNA in KRAS mutant versus KRAS wild-type
CRC patients in multivariate analysis could be explained
if AREG is viewed as a protein regulated by KRAS-
dependent transcription factors: the former group
includes tumours bearing KRAS mutations with a
markedly pro-survival, proliferative activating effect,
whereas the latter group includes KRAS wild type
tumours addicted to active EGFR signalling that is
amenable to abrogation by cetuximab.
Conclusions
Our study confirms published data on the prognostic/pre-
dictive significance of BRAF, KRAS mutations and on the
tumour expression of AREG, EREG mRNA in cetuximab-
treated patients with colorectal cancer. Moreover, we
present data suggesting a) a differential impact of non-
codon 12 KRAS mutations on outcome of cetuximab-
treated patients of Greek ethnic origin, b) a KRAS
mutation-independent predictive significance of EREG
mRNA expression, c) a strong predictive value of AREG
mRNA expression in KRAS wild type patients. These
findings warrant independent validation.
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